Literature DB >> 29661758

High TMB Predicts Immunotherapy Benefit.

.   

Abstract

The first data from the phase III CheckMate-227 trial of ipilimumab plus nivolumab for the treatment of non-small cell lung cancer suggests that the two drugs boost progression-free survival in patients with a high tumor mutation burden. After 1 year, progression-free survival was 43% for patients treated with the checkpoint inhibitor combination, compared with 13% for patients treated with chemotherapy. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29661758     DOI： 10.1158/2159-8290.CD-NB2018-048

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  15 in total

1.  Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

Authors:  Nadiya Hussain; Muntaha Naeem; David J Pinato
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

2.  Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.

Authors:  Guanghui Gao; Keyi Jia; Sha Zhao; Xuefei Li; Chao Zhao; Tao Jiang; Chunxia Su; Shengxiang Ren; Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network.

Authors:  Zexian Zeng; Jingxin Fu; Carrie Cibulskis; Aashna Jhaveri; Curtis Gumbs; Biswajit Das; Beatriz Sanchez-Espiridion; Sylvie Janssens; Daoud Meerzaman; Magdalena Thurin; Andrew Futreal; Chris Karlovich; Stacey B Gabriel; Ignacio Ivan Wistuba; X Shirley Liu; Catherine J Wu; Len Taing; Jin Wang; James Lindsay; Tomas Vilimas; Jianhua Zhang; Collin Tokheim; Avinash Sahu; Peng Jiang; Chunhua Yan; Dzifa Yawa Duose; Ethan Cerami; Li Chen; David Cohen; Qingrong Chen; Rebecca Enos; Xin Huang; Jack J Lee; Yang Liu; Donna S Neuberg; Cu Nguyen; Candace Patterson; Sharmistha Sarkar; Sachet Shukla; Ming Tang; Junko Tsuji; Mohamed Uduman; Xiaoman Wang; Jason L Weirather; Jijun Yu; Joyce Yu; Jianjun Zhang; Jiexin Zhang
Journal:  Clin Cancer Res       Date:  2020-12-15       Impact factor: 12.531

4.  Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden.

Authors:  Hong Yuan; Jun Ji; Min Shi; Yan Shi; Jing Liu; Junwei Wu; Chen Yang; Wenqi Xi; Qingyuan Li; Wei Zhu; Jingjie Li; Xiaoli Gong; Jun Zhang
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  Characterization of gene expression profiles of esophageal cancer patients with different nonsynonymous tumor mutation burden.

Authors:  Jiawei Li; Haiqing Chen; Haifa Guo; Mantang Qiu; Fan Yang
Journal:  Thorac Cancer       Date:  2020-06-17       Impact factor: 3.500

6.  Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.

Authors:  Lei Li; Xi Chen; Lu Hao; Qiuyan Chen; Haosheng Liu; Qing Zhou
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

7.  Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.

Authors:  Xiaoxiao Wang; Cheng Kong; Weizhang Xu; Sheng Yang; Dan Shi; Jingyuan Zhang; Mulong Du; Siwei Wang; Yongkang Bai; Te Zhang; Zeng Chen; Zhifei Ma; Jie Wang; Gaochao Dong; Mengting Sun; Rong Yin; Feng Chen
Journal:  Thorac Cancer       Date:  2019-08-14       Impact factor: 3.500

8.  Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.

Authors:  Bingxi He; Di Dong; Yunlang She; Caicun Zhou; Mengjie Fang; Yongbei Zhu; Henghui Zhang; Zhipei Huang; Tao Jiang; Jie Tian; Chang Chen
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

9.  Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody.

Authors:  Wenyue Zhou; Yuwen Zhou; Cheng Yi; Xinyao Shu; Guixia Wei; Xiaorong Chen; Xudong Shen; Meng Qiu
Journal:  Front Immunol       Date:  2021-09-29       Impact factor: 7.561

10.  Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer.

Authors:  Wenjie Li; Kezhi Zhou; Mengting Li; Qian Hu; Wanhui Wei; Lan Liu; Qiu Zhao
Journal:  BMC Gastroenterol       Date:  2022-02-05       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.